Literature DB >> 3379204

Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation.

P T Sager1, R A Perlmutter, L E Rosenfeld, C A McPherson, F J Wackers, W P Batsford.   

Abstract

To assess the effects of early thrombolytic therapy on the incidence of clinical and induced ventricular arrhythmias in high risk postmyocardial infarction patients, 32 patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation were prospectively evaluated. Sixteen patients (Group A) received routine care because of contraindication to thrombolytic therapy or other factors and 16 (Group B) received either tissue plasminogen activator or streptokinase within 6 h of the onset of chest pain. The two groups were similar in left ventricular ejection fraction (mean +/- SD, 28 +/- 9% [Group A] versus 30 +/- 8% [Group B]) and occurrence of spontaneous nonsustained ventricular tachycardia, new bundle branch block and congestive heart failure. Group B patients had higher peak creatine kinase MB levels (446 +/- 336 versus 205 +/- 120 IU; p = 0.017) and earlier time to peak creatine kinase values (13.4 +/- 6.6 versus 19.1 +/- 6.1 h; p = 0.006). Twenty patients who had no clinical sustained ventricular arrhythmias underwent electrophysiologic study 13 +/- 6 days after infarction. Ventricular tachycardia was induced during the study in 7 (88%) of 8 Group A patients, but in only 1 (8%) of 12 Group B patients given thrombolytic therapy (p = 0.0008). During a mean follow-up period of 11 +/- 8 months, eight Group A patients (50%) died suddenly or were resuscitated from sustained ventricular tachycardia; all Group B patients are alive and have had no clinical arrhythmic events (p = 0.002).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3379204     DOI: 10.1016/0735-1097(88)90350-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  The Open Artery Hypothesis: Past, Present, and Future.

Authors:  M Goel; J T Dodge; M Rizzo; C McLean; K A Ryan; W L Daley; C P Cannon; C M Gibson
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

2.  Benefits of late reperfusion in the treatment of acute myocardial infarction.

Authors:  Kinji Ishikawa
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

3.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

4.  The Open Artery: Electrophysiologic Considerations.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

5.  The Open-Artery Hypothesis: An Overview.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 6.  The open-artery hypothesis revisited.

Authors:  Alireza Zarrabi; Hossein Eftekhari; S Ward Casscells; Mohammad Madjid
Journal:  Tex Heart Inst J       Date:  2006

7.  Effect of thrombolysis on the evolution of late potentials within 10 days of infarction.

Authors:  M Eldar; J Leor; H Hod; Z Rotstein; S Truman; E Kaplinsky; S Abboud
Journal:  Br Heart J       Date:  1990-05

8.  Effects of Late Coronary Artery Reperfusion on Left Ventricular Remodeling Persist for 10 Weeks After Experimental Rat Myocardial Infarction and Are Associated with Improved Survival.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

9.  Significance of perfusion of the infarct related coronary artery for susceptibility to ventricular tachyarrhythmias in patients with previous myocardial infarction.

Authors:  H V Huikuri; M J Koistinen; K E Airaksinen; M J Ikäheimo
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

Review 10.  Risk stratification after myocardial infarction: role of electrical instability, ischemia, and left ventricular function.

Authors:  A Bayés-de-Luna; X Viñolas; J Guindo; A Bayés-Genis
Journal:  Cardiovasc Drugs Ther       Date:  1994-05       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.